ALFA Filings
Every announcement, straight from the exchange
Every Dr. Reddy's Laboratories regulatory approval announcement on NSE and BSE, newest first, each with its own page.
Time
2 announcements
Dr. Reddy's received DCGI approval for Zytorvi in advanced esophageal cancer, its second Indian indication. This expands first-line immunotherapy access in its oncology portfolio.
Dr. Reddy's Laboratories received a Notice of Compliance from Health Canada for its generic Semaglutide Injection. This approval authorizes the company to commercialize and distribute the product in Canada, marking a significant milestone in its GLP-1 therapy portfolio. Launch preparations for 2 mg and 4 mg pens are currently underway.